BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系

doi:10.11904/j.issn.1002-3070.2022.02.016

Abstract

Abstract: In recent years,immune checkpoint inhibitors(ICIs)have completely changed the treatment pattern of a variety of malignant tumors.However,not all patients can benefit from immunotherapy,and the overall effective rate is low.Therefore,how to screen the people who benefit from immunotherapy is currently a hot issue.Due to tumor heterogeneity,microenvironment complexity,specimen accessibility and other factors,the current biomarkers used to guide tumor immunotherapy have certain limitations.Studies have explored the predictive effect of clinical features on the efficacy of ICIs,including body mass index(BMI).This article reviews the relationship between BMI and the efficacy of immunotherapy for malignant tumors.

Key words: Malignant tumor, Body mass index, Immunotherapy, Immune checkpoint inhibitors

CLC Number:

R730.51

TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors[J]. Journal of Practical Oncology, 2022, 36(2): 188-192.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.02.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I2/188

References

1 Nosaki K,Saka H,Hosomi Y,et al.Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer:pooled analysis from the KEYNOTE-010,KEYNOTE-024,and KEYNOTE-042 studies[J].Lung Cancer,2019,135:188-195.
2 Ascierto PA,Del Vecchio M,Mandalá M,et al.Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma(CheckMate 238):4-year results from a multicentre,double-blind,randomised,controlled,phase 3 trial[J].Lancet Oncol,2020,21(11):1465-1477.
3 Motzer RJ,Tannir NM,Mcdermott DF,et al.Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma[J].N Engl J Med,2018,378(14):1277-1290.
4 Burtness B,Harrington KJ,Greil R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study[J].Lancet,2019,394(10212):1915-1928.
5 Gandhi L,Rodriguez-Abreu D,Gadgeel S,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J].N Engl J Med,2018,378(22):2078-2092.
6 Tay C,Qian Y,Sakaguchi S.Hyper-progressive disease:the potential role and consequences of T-regulatory cells foiling anti-PD-1 cancer immunotherapy[J].Cancers(Basel),2020,13(1):48.
7 Shen X,Zhao B.Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer:meta-analysis[J].BMJ,2018,362:3529.
8 Hellmann MD,Ciuleanu TE,Pluzanski A,et al.Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J].N Engl J Med,2018,378(22):2093-2104.
9 Khaddour K,Gomez-Perez SL,Jain N,et al.Obesity,sarcopenia,and outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors[J].Front Oncol,2020,10:576314.
10 Dimitrakopoulos FI,Nikolakopoulos A,Kottorou A,et al.PIOS(Patras Immunotherapy Score)score is associated with best overall response,progression-free survival,and post-immunotherapy overall survival in patients with advanced non-small-cell lung cancer(NSCLC)treated with anti-program cell death-1(PD-1)inhibitors[J].Cancers(Basel),2020,12(5):1257.
11 Dumenil C,Massiani MA,Dumoulin J,et al.Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab[J].PLoS One,2018,13(4):0195945.
12 Kichenadasse G,Miners JO,Mangoni AA,et al.Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer[J].JAMA Oncol,2020,6(4):512-518.
13 Cortellini A,Ricciuti B,Tiseo M,et al.Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥50%:a multicenter study with external validation[J].J Immunother Cancer,2020,8(2):001403.
14 Ichihara E,Harada D,Inoue K,et al.The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer[J].Lung Cancer,2020,139:140-145.
15 Wang F,Zhou L,Chen N,et al.The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy[J].Medicine(Baltimore),2021,100(8):24664.
16 Richtig G,Hoeller C,Wolf M,et al.Body mass index may predict the response to ipilimumab in metastatic melanoma:An observational multi-centre study[J].PLoS One,2018,13(10):e0204729.
17 Naik GS,Waikar SS,Johnson AEW,et al.Complex inter-relationship of body mass index,gender and serum creatinine on survival:exploring the obesity paradox in melanoma patients treated with checkpoint inhibition[J].J Immunother Cancer,2019,7(1):89.
18 Mcquade JL,Daniel CR,Hess KR,et al.Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy,immunotherapy,or chemotherapy:a retrospective,multicohort analysis[J].Lancet Oncol,2018,19(3):310-322.
19 Donnelly D,Bajaj S,Yu J,et al.The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients[J].J Immunother Cancer,2019,7(1):222.
20 Rutkowski P,Indini A,De Luca M,et al.Body mass index(BMI)and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy:a multicenter international retrospective study[J].J Immunother Cancer,2020,8(2):001117.
21 Xue Y,Gao S,Gou J,et al.Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors:preclinical and clinical studies and mechanism of action[J].Expert Opin Drug Deliv,2021,18(2):187-203.
22 Hosseini A,Gharibi T,Marofi F,et al.CTLA-4:From mechanism to autoimmune therapy[J].Int Immunopharmacol,2020,80:106221.
23 Skowron F,Berard F,Balme B,et al.Role of obesity on the thickness of primary cutaneous melanoma[J].J Eur Acad Dermatol Venereol,2015,29(2):262-269.
24 Brandon EL,Gu JW,Cantwell L,et al.Obesity promotes melanoma tumor growth:role of leptin[J].Cancer Biol Ther,2009,8(19):1871-1879.
25 Goebell PJ,Muller L,Hubner A,et al.Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry[J].Urol Oncol,2018,36(10):471-479.
26 Motzer RJ,Russo P,Haas N,et al.Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma:final overall survival analysis of the phase 3 PROTECT trial[J].Eur Urol,2021,79(3):334-338.
27 De Giorgi U,Procopio G,Giannarelli D,et al.Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab[J].Clin Cancer Res,2019,25(13):3839-3846.
28 Labadie BW,Liu P,Bao R,et al.BMI,irAE,and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma[J].J Transl Med,2019,17(1):386.
29 Sanchez A,Furberg H,Kuo F,et al.Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma:a cohort study[J].Lancet Oncol,2020,21(2):283-293.
30 Boi SK,Orlandella RM,Gibson JT,et al.Obesity diminishes response to PD-1-based immunotherapies in renal cancer[J].J Immunother Cancer,2020,8(2):e000725.
31 Fan X,Wang D,Zhang W,et al.Inflammatory markers predict survival in patients with advanced gastric and colorectal cancers receiving anti-PD-1 therapy[J].Front Cell Dev Biol,2021,9:638312.
32 Bally AP,Austin JW,Boss JM.Genetic and epigenetic regulation of PD-1 expression[J].J Immunol,2016,196(6):2431-2437.
33 Bu LL,Yu GT,Wu L,et al.STAT3 induces immunosuppression by upregulating PD-1/PD-L1 in HNSCC[J].J Dent Res,2017,96(9):1027-1034.
34 Rasouli N,Kern PA.Adipocytokines and the metabolic complications of obesity[J].J Clin Endocrinol Metab,2008,93(11 Suppl 1):64-73.
35 Wang Z,Aguilar EG,Luna JI,et al.Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade[J].Nat Med,2019,25(1):141-151.

[1]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[2]	WANG Yanping, QIU Lin, WU Meng, SA Rina. Analysis of the incidence and mortality of malignant tumors in Shaanxi province in 2016 [J]. Journal of Practical Oncology, 2022, 36(1): 1-6.
[3]	LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 49-53.
[4]	WANG Siran, HU Weiping. Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(1): 79-83.
[5]	YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 542-546.
[6]	YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 552-556.
[7]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[8]	FU Yan¹, YAN Lili², WANG Chunyu², FU Fangmin², DONG Hua³. Analysis for the prevalence of malignant tumors in Qionghai city from 2010 to 2016 [J]. Journal of Practical Oncology, 2021, 35(5): 396-401.
[9]	ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy [J]. Journal of Practical Oncology, 2021, 35(5): 441-446.
[10]	JIN Shengye, PANG Da. Research progress in the mechanism of oncolytic virus inducing tumor apoptosis and activating anti-tumor immunity [J]. Journal of Practical Oncology, 2021, 35(5): 462-467.
[11]	FAN Lin, TIAN Linli, LIU Ming. Research and development of single-cell sequencing technology in head and neck malignant tumors [J]. Journal of Practical Oncology, 2021, 35(5): 472-475.
[12]	DONG Hua, WANG Dingbin, HUA Jing, FAN Kangqiong, MA Nannan, WANG Xingren. Analysis for the incidence and death of malignant tumors in Hainan cancer registry,2016 [J]. Journal of Practical Oncology, 2021, 35(4): 344-350.
[13]	CHEN Lili, LIU Yuqin, DING Gaoheng, SU Haixiang. Epidemic situation about prevention and control of malignant tumor in Gansu province [J]. Journal of Practical Oncology, 2021, 35(3): 254-257.
[14]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[15]	GUO Haonan, QIN Tao. Research progress of MYO10 and malignant tumors [J]. Journal of Practical Oncology, 2021, 35(3): 273-276.

The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments